ReviewArthritis research & therapy2007
Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?
Review in Arthritis research & therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.Clinical rheumatology · 2011Trial
- TAp63, a methotrexate target in CD4+ T cells, suppresses Foxp3 expression and exacerbates autoimmune arthritis.JCI insight · 2023Article
- The effect of concomitant hand osteoarthritis on pain and disease activity in patients with rheumatoid arthritis.Clinical rheumatology · 2019Article
- Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol.Medicine · 2018Article
- Biological tapering and sonographic flare in rheumatoid arthritis.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2018Observational
- Work instability in rheumatoid arthritis patients from Argentina: prevalence and associated factors.Rheumatology international · 2015Observational
- Ultrasonographic assessment reveals detailed distribution of synovial inflammation in Blau syndrome.Arthritis research & therapy · 2014Article
- Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?Therapeutic advances in musculoskeletal disease · 2010Article
- Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.Drug, healthcare and patient safety · 2010Article
- Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis.Arthritis research & therapy · 2010Article
- Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy.Clinical rheumatology · 2009Article
- Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis.Arthritis research & therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis factor (TNF)-blocking drugs and methotrexate produces superior outcomes over monotherapy alone; however, use is limited by cost and potential side-effects. Currently, anti-TNF therapy is normally reserved for patients who have failed traditional disease-modifying anti-rheumatic drugs. The question that remains is whether TNF-blocking drugs are better used if given early; the high direct costs are countered by both direct and indirect savings in healthcare costs from optimal control of disease, and the benefits of early control outweigh the increased risk of infection and malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.